New cancer treatment technology gets $1m grant from Australian govt 

A $1 million grant from the Australian Government will accelerate the commercialization of MOSkin™, a revolutionary medical radiation sensor developed by the University of Wollongong’s Centre for Medical Radiation Physics, poised to transform cancer treatment.
MOSkin™, developed by a team led by Prof Anatoly Rozenfeld, is hailed as the world’s most advanced and cost-effective dosimetry tool; a small adhesive panel, when applied to a patient’s skin, precisely measures radiation doses during radiotherapy, reducing the risk of side effects like skin burns and damage to surrounding tissues.
Electrogenics Laboratories Ltd CEO Geoff Neilson says this grant provided under the Industry Growth Program will accelerate their efforts to advance MOSkin™ technology, ensuring safer and more effective radiotherapy treatments while providing faster, more reliable results for clinicians. “We are committed to leveraging this opportunity to drive Australian medtech innovation forward,” he added.
Radiation is vital in procedures like angiograms, diagnostic scans, and radiotherapy, essential for treating up to 50% of cancer patients, but current radiation dose measurement methods often lack accuracy and reliability.
Prof Rozenfeld emphasized the device’s potential to improve patient care, saying that more than 50pc of cancer patients undergo radiotherapy, but until now, there was no precise method to measure skin dosage at the treatment site. He added that this device ensures accurate dosimetry, minimizing damage to the skin, the body's largest organ, 
“Improving treatment and quality of life for patients is a deeply personal mission for me, especially after losing both parents to cancer,” he said.
Both Prof Rozenfeld and Mr. Neilson highlighted the importance of their collaboration in bringing MOSkin™ to market. “MOSkin™ represents years of dedicated work and innovation from both researchers and industry partners. The Industry Growth Program grant is vital at this critical stage,” said Prof Rozenfeld.
“Our partnership with UOW has been instrumental in expediting our progress,” said Mr. Neilson, adding that they look forward to continuing this successful collaboration, moving toward market launch.
Meanwhile, the UoW reaffirms its commitment to advancing the United Nations Sustainable Development Goals, particularly Goal 3 (Good Health and Wellbeing) and Goal 9 (Industry, Innovation, and Infrastructure), through initiatives like MOSkin™.